AgeX Therapeutics 55336VAG5 Bond
AGEDelisted Stock | USD 0.74 0.01 1.37% |
AgeX Therapeutics holds a debt-to-equity ratio of 0.75. . AgeX Therapeutics' financial risk is the risk to AgeX Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
AgeX Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. AgeX Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps AgeX Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect AgeX Therapeutics' stakeholders.
For most companies, including AgeX Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for AgeX Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, AgeX Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
AgeX |
Given the importance of AgeX Therapeutics' capital structure, the first step in the capital decision process is for the management of AgeX Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of AgeX Therapeutics to issue bonds at a reasonable cost.
Popular Name | AgeX Therapeutics MPLX LP 4875 |
Equity ISIN Code | US00848H1086 |
Bond Issue ISIN Code | US55336VAG59 |
S&P Rating | Others |
Maturity Date | 1st of December 2024 |
Issuance Date | 1st of June 2016 |
Coupon | 4.875 % |
AgeX Therapeutics Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
ADVGRO 8625 30 SEP 27 | US00840KAA79 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
US00842XAA72 | US00842XAA72 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
US00846UAL52 | US00846UAL52 | Details | |
AGILENT TECHNOLOGIES INC | US00846UAK79 | Details | |
AGILENT TECHNOLOGIES INC | US00846UAN19 | Details | |
Agilent Technologies 21 | US00846UAM36 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
International Game Technology | US460599AD57 | Details | |
BNP Paribas FRN | USF1R15XK367 | Details | |
MGM Resorts International | US552953CD18 | Details | |
AerCap Global Aviation | US00773HAA59 | Details |
Understaning AgeX Therapeutics Use of Financial Leverage
AgeX Therapeutics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures AgeX Therapeutics' total debt position, including all outstanding debt obligations, and compares it with AgeX Therapeutics' equity. Financial leverage can amplify the potential profits to AgeX Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if AgeX Therapeutics is unable to cover its debt costs.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. Agex Therapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people. Please read more on our technical analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in AgeX Stock
If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.